Impact of Brokerage Rating on Juno Therapeutics, Inc.(JUNO)

Many Juno Therapeutics, Inc.(JUNO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Juno Therapeutics Inc was Initiated by Wedbush on Feb 2, 2017 to Neutral, Price Target of the shares are set at $24.Juno Therapeutics Inc was Downgraded by Raymond James to Mkt Perform on Dec 6, 2016. Juno Therapeutics Inc was Downgraded by SunTrust on Nov 25, 2016 to Hold, Lowers Price Target to $ 25 from a previous price target of $48 .Juno Therapeutics Inc was Downgraded by FBR & Co. on Nov 23, 2016 to Mkt Perform, Price Target of the shares are set at $30.Juno Therapeutics Inc was Reiterated by Maxim Group on Nov 23, 2016 to Buy, Lowers Price Target to $ 34 from a previous price target of $50 .

Company has reported several Insider transactions to the SEC, on Nov 10, 2016, Robert Azelby (EVP & Chief Commercial Officer) sold 12,921 shares at 24.14 per share price.On Sep 29, 2016, Hans Edgar Bishop (CEO & President) sold 44,000 shares at 33.00 per share price.On Jun 24, 2016, Richard Klausner (director) sold 12,000 shares at 40.71 per share price.

Juno Therapeutics Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.58. The company had revenue of $20.80 million for the quarter, compared to analysts expectations of $11.31 million. The companys revenue was up 1200.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.

Juno Therapeutics, Inc. (NASDAQ:JUNO) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 2.4 by 10 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 7 Brokerage Firms have advised hold.

Juno Therapeutics, Inc. (NASDAQ:JUNO): According to 9 Analysts, The short term target price has been estimated at $ 35.89.The target price could deviate by a maximum of $9.74 from the forecast price. In the near term, the target price could hit a high of $51 and a low of $ 24.

Juno Therapeutics, Inc. (NASDAQ:JUNO) rose 1.92% or 0.425 points on Tuesday and made its way into the gainers of the day. After trading began at $21.95 the stock was seen hitting $22.59 as a peak level and $21.75 as the lowest level. The stock ended up at $22.535. The daily volume was measured at 1,247,377 shares. The 52-week high of the share price is $49.72 and the 52-week low is $17.52. The company has a market cap of $2,386 million.

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.

Juno

For any feedback and suggestions contact author at Scott.Taylor@thefoundersdaily.com

Add Comment